Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Clinical Programs
    • IRAK1/4
    • RIPK1
    • Partnered Programs
    • Clinical Trials
    • Investigator Sponsored Research
    • Expanded Access Policy
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • ESG
  • News & Events

  • Press Releases
  • Events & Presentations
  • Email Alerts
May 06, 2025 4:01pm EDT

Rigel Reports First Quarter 2025 Financial Results and Provides Business Update

Apr 29, 2025 8:05am EDT

Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update

Mar 27, 2025 8:05am EDT

Rigel Announces Settlement Agreement Resolving TAVALISSE® (fostamatinib disodium hexahydrate) Patent Litigation

Mar 10, 2025 8:05am EDT

Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors

Mar 04, 2025 4:01pm EST

Rigel Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 25, 2025 8:05am EST

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update

Jan 22, 2025 8:05am EST

Rigel's Fostamatinib Being Studied by National Institute of Health in Patients with Sickle Cell Disease

Jan 13, 2025 8:05am EST

Rigel Provides Business Update and 2025 Outlook

Jan 09, 2025 8:05am EST

Rigel Announces R289 Granted Orphan Drug Designation by the FDA for MDS

Jan 08, 2025 8:05am EST

Rigel to Present at the 43rd Annual J.P. Morgan Healthcare Conference

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • …41
  • Next
RSS
  • Email Alerts
  • RSS News Feed
Terms of Use Privacy Policy Your Cookie Preferences

© 2025 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, REZLIDHIA, GAVRETO, RIGEL and the Rigel arc logo are registered trademarks of Rigel Pharmaceuticals, Inc.

Facebook Twitter Linkedin